Bemnifosbuvir/Ruzasvir - ATEA pharmaceuticals
Alternative Names: Ruzasvir/Bemnifosbuvir - ATEA pharmaceuticalsLatest Information Update: 07 Aug 2024
At a glance
- Originator Atea Pharmaceuticals
- Class Amines; Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Fluorinated hydrocarbons; Imidazoles; Indoles; Phosphorus compounds; Purine nucleotides; Pyrrolidines; Small molecules; Thiazoles
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis C; Unspecified
Most Recent Events
- 15 Apr 2024 Phase-I clinical trials in Unspecified (In volunteers, Combination therapy) in Canada (unspecified route) (NCT06356194)
- 15 Apr 2024 Phase-I clinical trials in Unspecified (In volunteers, Monotherapy) in Canada (unspecified route) (NCT06356194)
- 10 Apr 2024 Atea Pharmaceuticals plans a phase I trial (In volunteers) in Canada (NCT06356194)